Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Pfizer and Synthon Enter Into U.S. Commercialization Agreement for Potential Generic Treatment of Multiple Sclerosis
Therapeutic Testosterone Administration Preserves Excitatory Synaptic Transmission in the Hippocampus during Autoimmune Demyelinating Disease.
Co-enzyme Q10 and idebenone use in Friedreich's ataxia.
Dopaminergic Modulation of CD4+CD25 Regulatory T Lymphocytes in Multiple Sclerosis Patients during Interferon-β Therapy.
Disease Modifying Potential of Glatiramer Acetate in Huntington's Disease.
Genzyme’s Lemtrada™ approved in Australia for treatment of multiple sclerosis
Inhibition of glycerophosphate-dependent H2O2 generation in brown fat mitochondria by idebenone.
Altered CD4+/CD8+ T-cell ratios in cerebrospinal fluid of natalizumab-treated patients with multiple sclerosis.
Pelvic Floor Muscle Training With and Without Electrical Stimulation in the Treatment of Lower Urinary Tract Symptoms in Women With Multiple Sclerosis.
[Plasmapheresis in central nervous system disorders].
Effectiveness of Natalizumab in Patients with Highly Active Relapsing Remitting Multiple Sclerosis.
Vitamin D receptor binding, chromatin states and association with multiple sclerosis.
It is better to be in a clinical trial than not: lessons learnt from clinical neurology--the management of acute multiple sclerosis relapses.
Myasthenia gravis and neuromyelitis optica spectrum disorder: A multicenter study of 16 patients.
Cranial neuropathies in multiple sclerosis defined by magnetic resonance imaging and fludeoxyglucose f 18 positron emission tomography.
Validation of a Dutch version of the Neurological Fatigue Index (NFI-MS) for patients with multiple sclerosis in the Netherlands.
The microbial metabolites, short-chain fatty acids, regulate colonic Treg cell homeostasis.
Generic Midamor
Ono to enter license agreements with Merck KGaA
Clinical and immunological follow-up of B-cell depleting therapy in CNS demyelinating diseases.
Double blind placebo-controlled Phase I/II clinical trial of idebenone in patients with primary progressive multiple sclerosis (IPPoMS)
Acorda Therapeutics announces top line results of post-marketing commitment study exploring 5 mg dose of dalfampridine-ER
Exploratory analysis of predictors of patient adherence to subcutaneous interferon beta-1a in multiple sclerosis: TRACER study.
Epstein-Barr virus in the multiple sclerosis brain: a controversial issue--report on a focused workshop held in the Centre for Brain Research of the Medical University of Vienna, Austria.
Leber's hereditary optic neuropathy associated with multiple sclerosis: Harding's syndrome.

Pages